Follow-up: ICD-10-CM’s guidelines state that “the follow-up Z code categories imply that the condition has been fully treated and no longer exists.” The codes in question are: Z08 (Encounter for follow-up examination after completed treatment for malignant neoplasm) Z09 (... for conditions other than malignant neoplasm)
Other abnormal tumor markers. R97.8 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2019 edition of ICD-10-CM R97.8 became effective on October 1, 2018.
Encounter for follow-up examination after completed treatment for malignant neoplasm. Z08 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
Encounter for follow-up examination after completed treatment for malignant neoplasm. Z08 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2019 edition of ICD-10-CM Z08 became effective on October 1, 2018.
Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm. Z09 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2020 edition of ICD-10-CM Z09 became effective on October 1, 2019.
ICD-10 code Z09 for Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
LOINC MapOrder CodeOrder Code NameResult Code002253AFP, Serum, Tumor Marker002266
Elevated carcinoembryonic antigen [CEA] R97. 0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM R97. 0 became effective on October 1, 2021.
Z12. 11: Encounter for screening for malignant neoplasm of the colon.
The carcinoembryonic antigen (CEA) test measures the level of CEA in the blood. CEA is a protein normally found in the tissue of a developing baby in the womb. The blood level of this protein disappears or becomes very low after birth. In adults, an abnormal level of CEA may be a sign of cancer.
Tumor tissue (or cell) markers are found in the actual tumors themselves, typically in a sample of the tumor that is removed during a biopsy. Tumor tissue markers are used to: diagnose, stage, and/or classify cancer. estimate prognosis.
CEA is a protein polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring the response of certain malignancies to therapy. CEA may be medically necessary for follow-up of patients with colorectal carcinoma.
To summarize, NCD 190.26 provides, under the heading “Indications,” that a CEA test “may be medically necessary,” and thus covered by Medicare, for two broad groups of patients: (1) patients with colorectal cancer; and (2) patients with other types of cancer when the cancer tumor does not express a “more specific ...
CA 19-9 is a type of tumor marker. Tumor markers are substances made by cancer cells or by normal cells in response to cancer in the body. Healthy people can have small amounts of CA 19-9 in their blood. High levels of CA 19-9 are often a sign of pancreatic cancer.
For example, Z12. 31 (Encounter for screening mammogram for malignant neoplasm of breast) is the correct code to use when you are ordering a routine mammogram for a patient. However, coders are coming across many routine mammogram orders that use Z12. 39 (Encounter for other screening for malignant neoplasm of breast).
Z12. 12 Encounter for screening for malignant neoplasm of rectum - ICD-10-CM Diagnosis Codes.
If the patient presents for a screening colonoscopy and a polyp or any other lesion/diagnosis is found, the primary diagnosis is still going to be Z12. 11, Encounter for screening for malignant neoplasm of colon. The coder should also report the polyp or findings as additional diagnosis codes.
The 2022 edition of ICD-10-CM Z08 became effective on October 1, 2021.
In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere.". Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code.
The 2022 edition of ICD-10-CM Z09 became effective on October 1, 2021.
Z09- Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm
In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere.". Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code.
Note: For follow-up imaging following completed surgical treatment for non-cancerous conditions (including benign neoplasms), you will report Z09 (Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm).
In this case, you can report J95.830 (Postprocedural hemorrhage of a respiratory system organ or structure following a respiratory system procedure).
You will report G89.28 (Other chronic postprocedural pain) as a secondary diagnosis.
However, you shouldn’t necessarily jump to report Z08 (Encounter for follow-up examination after completed treatment for malignant neoplasm) just because the dictation report documents no traces of remaining malignancy.
Typically, you would not consider reporting the pain separately since it’s a clear and obvious symptom of the postprocedural hemorrhage. However, have a look at these ICD-10-CM instructions on postprocedural pain coding:
Contrast the follow-up codes to the main group of aftercare codes, Z42-Z51, which ICD-10 clarifies “are for patients who have already been treated for a disease or injury, but who are receiving aftercare.” These codes are much more detailed
Ob-gyn coders will be most familiar with Z39.2 (Encounter for routine postpartum follow-up), but just as frequently the code Z08 will be reported by a gyn oncologist who is seeing the patient 6 months postop a hysterectomy for cancer, says Melanie Witt, RN, MA, an ob-gyn coding expert based in Guadalupita, N.M.
This group of aftercare codes, the Z51 (Encounter for other aftercare and medical care ) code group, can also be confusing. Because the variations of Z51 are so specific, like Z42-Z49, they are mutually exclusive to Z08 and Z09.
As Witt explains, coders “would not usually use the Z code for a recheck for an injury because they will normally use the injury diagnosis code with a subsequent encounter. This means the injury, accident, or poisoning is now in the healing stage.”
in nature and include such ob-gyn-oriented encounters as Z44.8 (Encounter for fitting and adjustment of other external prosthetic devices ) when the patient presents for Pessary care, and Z48.02 (Encounter for removal of sutures).
When you think of follow-up, you probably think of ongoing treatment for a patient . Quite logically, you might even think of other, similar terminology like “aftercare,” “monitoring,” or “surveillance.” But when it comes to encounter codes, each one of these terms carries a different, specific meaning that could have a big impact on your ongoing care coding.
While you’ll use Z08 for follow-up exams after a malignant neoplasm, you’ll use Z09 for all follow-up visits when the patient has finished their treatment plan, such as antibiotics, steroids, any type of medication, regardless of who put the patient on the medication. Coders, Witt explains, “need to use this code first and then use a secondary code for a history of a disease.”
CPT codes, descriptions and other data only are copyright 2021 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use.
Social Security Act (Title XVIII) Standard References: Title XVIII of the Social Security Act, Section 1833 (e) states that no payment shall be made to any provider of services or other person under this part unless there has been furnished such information as may be necessary in order to determine the amounts due such provider or other person under this part for the period with respect to which the amounts are being paid or for any prior period..
This Billing and Coding Article provides billing and coding guidance for Local Coverage Determination (LCD) L35396, Biomarkers for Oncology.
It is the provider’s responsibility to select codes carried out to the highest level of specificity and selected from the ICD-10-CM code book appropriate to the year in which the service is rendered for the claims (s) submitted. Please use the following link to NCD 90.2, Next Generation Sequencing (NGS) for Patients with Advanced Cancer, for a list of ICD-10-CM diagnosis codes for NGS allowable for CPT code 0022U: https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=372&ncdver=1&bc=AAAAQAAAAAAA.
All those not listed under the “ICD-10 Codes that Support Medical Necessity” section of this article.
Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type.
Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination.